Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
NCT ID: NCT00206089
Last Updated: 2010-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
3300 participants
INTERVENTIONAL
2005-09-30
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EXANTA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female or male aged 18 years and over
* Patient scheduled for primary elective hip replacement or patient requiring surgery for hip fracture.
Exclusion Criteria
* Conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency.
* Myocardial infarction, Ischemic stroke or Transient Ischemic Attack (TIA), systemic embolism or venous thrombo-embolism within 30 days of enrollment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Graz, , Austria
Research Site
Innsbruck, , Austria
Research Site
Leoben, , Austria
Research Site
Neunkirchen, , Austria
Research Site
Neustadt, , Austria
Research Site
Sankt Johann in Tirol, , Austria
Research Site
Viborg, , Austria
Research Site
Vienna, , Austria
Research Site
Wels, , Austria
Research Site
Brussels, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Aarhus, , Denmark
Research Site
Glostrup Municipality, , Denmark
Research Site
Hellerup, , Denmark
Research Site
Herlev, , Denmark
Research Site
Hillerød, , Denmark
Research Site
Holstebro, , Denmark
Research Site
Hvidovre, , Denmark
Research Site
Hørsholm, , Denmark
Research Site
Silkeborg, , Denmark
Research Site
Vejle, , Denmark
Research Site
Hus, , Finland
Research Site
Jyväskylä, , Finland
Research Site
Kuopio, , Finland
Research Site
Oys, , Finland
Research Site
Tampere, , Finland
Research Site
Turku, , Finland
Research Site
Amiens, , France
Research Site
Annecy, , France
Research Site
Caen, , France
Research Site
Créteil, , France
Research Site
Le Kremlin-Bicêtre, , France
Research Site
Montpellier, , France
Research Site
Nice, , France
Research Site
Paris, , France
Research Site
Saint-Etienne, , France
Research Site
Bad Mergentheim, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Essen, , Germany
Research Site
Frankfurt, , Germany
Research Site
Garmisch-Partenkirchen, , Germany
Research Site
Halle, , Germany
Research Site
Rheinfelden, , Germany
Research Site
Sommerfeld, , Germany
Research Site
Wiesbaden, , Germany
Research Site
Budapest, , Hungary
Research Site
Gyula, , Hungary
Research Site
Gyzr, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Pécs, , Hungary
Research Site
Szeged, , Hungary
Research Site
Székesthérvár, , Hungary
Research Site
Estado de México, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Mexico City, , Mexico
Research Site
Assen, , Netherlands
Research Site
Breda, , Netherlands
Research Site
Groningen, , Netherlands
Research Site
Hilversum, , Netherlands
Research Site
Leeuwarden, , Netherlands
Research Site
Sittard, , Netherlands
Research Site
Zaandam, , Netherlands
Research Site
Zwolle, , Netherlands
Research Site
Ålesund, , Norway
Research Site
Bergen, , Norway
Research Site
Bodø, , Norway
Research Site
Drammen, , Norway
Research Site
Elverum, , Norway
Research Site
Gjettum, , Norway
Research Site
Hagavik, , Norway
Research Site
Kongsberg, , Norway
Research Site
Kongsvinger, , Norway
Research Site
Larvik, , Norway
Research Site
Levanger, , Norway
Research Site
Lillehammer, , Norway
Research Site
Nordbyhagen, , Norway
Research Site
Oslo, , Norway
Research Site
Skien, , Norway
Research Site
Stavanger, , Norway
Research Site
Trondheim, , Norway
Research Site
Biaystok, , Poland
Research Site
Bydgoszcz, , Poland
Research Site
Chojnice, , Poland
Research Site
Gdansk, , Poland
Research Site
Lublin, , Poland
Research Site
Od, , Poland
Research Site
Warsaw, , Poland
Research Site
Wrocraw, , Poland
Research Site
Barreiro, , Portugal
Research Site
Cascais, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Parede, , Portugal
Research Site
Setúbal, , Portugal
Research Site
Torres Vedras, , Portugal
Research Site
Vila Franca de Xira, , Portugal
Research Site
Durban, , South Africa
Research Site
Gauteng, , South Africa
Research Site
Sandton, , South Africa
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Ourense, , Spain
Research Site
Santander, , Spain
Research Site
Valencia, , Spain
Research Site
Borås, , Sweden
Research Site
Falköping, , Sweden
Research Site
Falun, , Sweden
Research Site
Gothenburg, , Sweden
Research Site
Jönköping, , Sweden
Research Site
Kalmar, , Sweden
Research Site
Kungälv, , Sweden
Research Site
Linköping, , Sweden
Research Site
Lund, , Sweden
Research Site
Mölndal, , Sweden
Research Site
Örebro, , Sweden
Research Site
Skövde, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Uddevalla, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Basel, , Switzerland
Research Site
Bern, , Switzerland
Research Site
Geneva, , Switzerland
Research Site
Lugano, , Switzerland
Research Site
Luzem, , Switzerland
Research Site
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; EXTEND Study Group. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123(3):488-97. doi: 10.1016/j.thromres.2008.02.017. Epub 2008 May 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D4003C00030
Identifier Type: -
Identifier Source: org_study_id